文献速递神经MR

无增强MRI在多发性硬化新发脑病灶检测中的准确性

Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis.
PubMed 文献 · Radiology · 2019-03-12

本回顾性研究基于前瞻性观察队列,评估507次随访MRI中增强T1WI与平扫DIR/FLAIR减影图检测多发性硬化新发或增大病灶的差异。207个强化病灶中仅4个(1.9%)仅在平扫发现,无任何图像因增强序列而改变间隔进展诊断;3.0T下钆对比剂未改变进展评估。

要点

  • 平扫DIR/FLAIR减影图可检测绝大多数新发或增大病灶,仅0.2%病灶仅见于增强T1WI。
  • 增强序列未在507次随访中额外发现任何间隔进展,平扫读数即可判定进展。
  • 阅片者间一致性高:FLAIR ICC 0.91、DIR ICC 0.94、增强T1WI ICC 0.99。

核心结论

  • 在3.0T下,随访MRI使用钆对比剂未改变多发性硬化患者间隔疾病进展的诊断。

研究设计与样本

  • 基于本地前瞻性观察队列的回顾性研究,纳入359例多发性硬化患者(平均年龄38.2岁±10.3;246女、113男)的507次随访MR图像,两名阅片者独立盲法评估平扫DIR、FLAIR减影图与增强T1WI(钆特酸葡胺0.1 mmol/kg)。

关键影像表现/征象

  • 507次随访图像中264次显示间隔进展,共1992个新发或增大病灶和207个强化病灶。
  • 4个病灶(见于3次MR图像)仅回顾性见于平扫图像,占强化病灶的1.9%(4/207)、全部新发或增大病灶的0.2%(4/1992)。
  • 9个强化病灶未在基于FLAIR的减影图上检出(9/1442,0.6%)。

诊断标准与关键数值

  • 间隔进展定义为随访MR图像上至少一个新发或明确增大的病灶。
  • 仅增强T1WI检出而平扫未检出的新发或增大病灶比例为0/1992。
  • 阅片者间一致性ICC:FLAIR 0.91、DIR 0.94、增强T1WI 0.99。

临床应用与阅片要点

  • 平扫DIR和FLAIR减影图读数足以判定多发性硬化随访中的间隔进展,增强序列未额外提供进展信息。
  • 基于FLAIR的减影图可能遗漏少量强化病灶(9/1442,0.6%),读片时需结合DIR减影图综合判断。

局限性

  • 本文为回顾性研究,基于本地前瞻性观察队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Administration of a gadolinium-based contrast material is widely considered obligatory for follow-up imaging of patients with multiple sclerosis (MS). However, advances in MRI have substantially improved the sensitivity for detecting new or enlarged lesions in MS. Purpose To investigate whether the use of contrast material has an effect on the detection of new or enlarged MS lesions and, consequently, the assessment of interval progression. Materials and Methods In this retrospective study based on a local prospective observational cohort, 507 follow-up MR images obtained in 359 patients with MS (mean age, 38.2 years ± 10.3; 246 women, 113 men) were evaluated. With use of subtraction maps, nonenhanced images (double inversion recovery [DIR], fluid-attenuated inversion recovery [FLAIR]) and contrast material-enhanced (gadoterate meglumine, 0.1 mmol/kg) T1-weighted images were separately assessed for new or enlarged lesions in independent readings by two readers blinded to each other's findings and to clinical information. Primary outcome was the percentage of new or enlarged lesions detected only on contrast-enhanced T1-weighted images and the assessment of interval progression. Interval progression was defined as at least one new or unequivocally enlarged lesion on follow-up MR images. Results Of 507 follow-up images, 264 showed interval progression, with a total of 1992 new or enlarged and 207 contrast-enhancing lesions. Four of these lesions (on three MR images) were retrospectively detected on only the nonenhanced images, corresponding to 1.9% (four of 207) of the enhancing and 0.2% (four of 1992) of all new or enlarged lesions. Nine enhancing lesions were not detected on FLAIR-based subtraction maps (nine of 1442, 0.6%). In none of the 507 images did the contrast-enhanced sequences reveal interval progression that was missed in the readouts of the nonenhanced sequences, with use of either DIR- or FLAIR-based subtraction maps. Interrater agreement was high for all three measures, with intraclass correlation coefficients of 0.91 with FLAIR, 0.94 with DIR, and 0.99 with contrast-enhanced T1-weighted imaging. Conclusion At 3.0 T, use of a gadolinium-based contrast agent at follow-up MRI did not change the diagnosis of interval disease progression in patients with multiple sclerosis. © RSNA, 2019 See also the editorial by Saindane in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Eichinger P, Schön S, Pongratz V, et al. Accuracy of Unenhanced MRI in the Detection of New Brain Lesions in Multiple Sclerosis. Radiology. 2019. PMID: 30860448. doi:10.1148/radiol.2019181568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。